De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
Mult Scler
; 25(4): 618-621, 2019 04.
Article
em En
| MEDLINE
| ID: mdl-30375922
ABSTRACT
BACKGROUND:
Dalfampridine extended release (DAL) is a broad-spectrum voltage-gated potassium channel blocker that is indicated in multiple sclerosis to improve the nerve conduction of demyelinated axons. Seizures are a known side effect of DAL, which is contraindicated in patients with a history of epilepsy.OBJECTIVE:
Three cases of multiple sclerosis (MS) with de novo convulsive status epilepticus (CSE) probably related to dalfampridine administration are described.METHODS:
No patients had a history of seizures or renal impairment. Biological tests were normal. A brain magnetic resonance imaging (MRI) showed diffuse cortical and subcortical atrophy without active inflammatory lesions.RESULTS:
All three patients presented with CSE that was attributed to DAL and so was discontinued.CONCLUSION:
These case reports illustrate that, aside from seizures, de novo CSE is a potential complication of MS patients treated with DAL.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Estado Epiléptico
/
4-Aminopiridina
/
Bloqueadores dos Canais de Potássio
/
Esclerose Múltipla
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article